Published in final edited form as:

Cancer Chemother Pharmacol. 2012 April ; 69(4): 1107–1111. doi:10.1007/s00280-011-1820-8.

Ugt1a is required for the protective effect of selenium against irinotecan-induced toxicity

Shousong Cao,

Department of Cancer Biology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA

Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA

Farukh A. Durrani,

Department of Cancer Biology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA

Youcef M. Rustum, and

Department of Cancer Biology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA

Y. Eugene Yu

Department of Cancer Genetics, Center for Genetics and Pharmacology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA

Abstract

Purpose—Irinotecan (CPT-11) is widely used for the treatment of patients with colorectal cancer. However, the adverse effects associated with the treatment have hindered the efficacies of irinotecan. We have shown that organic selenium compounds could significantly attenuate irinotecan-associated toxicity and enhance antitumor activity in xenograft tumor models. The objective of this study is to determine the role of a specific group of uridine diphosphate glucuronosyltransferases, which is coded by *UGT1A*, in detoxification process of irinotecan as well as selenium-associated protective effect against irinotecan-induced toxicity.

Methods—In this study, the toxicities of irinotecan, docetaxel and cisplatin in the *Ugt1a* mutant rats and their wild-type controls were compared. The plasma concentrations of irinotecan and SN-38 were measured. The modulatory effect of a selenium compound on irinotecan-induced toxicity was analyzed in these rats.

Results—We demonstrated that the maximum tolerated doses of irinotecan in the homozygous mutant rats were significantly lower than those in wild-type rats, 25 mg/kg $\times$ 1 vs. 200 mg/kg $\times$ 1, and 3 mg/kg/day $\times$ 3 vs. 100 mg/kg/day $\times$ 3, respectively. The enhanced sensitivity was specific to irinotecan and was not observed with other chemotherapeutic agents, such as docetaxel and cisplatin, where *Ugt1a* is not required for their metabolism. Our results also showed that selective protection against irinotecan induced toxicity by 5-methylselenocysteine was achieved in the wild-type rats but not in the *Ugt1a* null rats.

Conclusion—These data support the hypothesis that expression of *UGT1A* is critical for 5-methylselenocysteine to exert its protective effect against irinotecan-induced toxicity.

Correspondence to: Shousong Cao; Y. Eugene Yu.

Shousong.Cao@roswellpark.org Yuejin.Yu@roswellpark.org.

Conflict of Interest statement. None of the authors has any conflict of interest.

INTRODUCTION

As a chemotherapeutic agent, irinotecan is used extensively in the treatment of cancers, particularly colorectal cancer [1]. Irinotecan is converted by carboxylesterases to its active metabolite, SN-38, which can stabilize ternary complexes between topoisomerase I and DNA and thereby cause replication fork arrest and double-stranded DNA breaks [2-6]. In combination therapy, irinotecan together with 5-fluorouracil and leucovorin can lead to positive responses in about half the patients with advanced colorectal cancer, but 20-30% of these patients develop severe adverse responses, such as diarrhea and neutropenia [7, 8]. This dose-limiting toxicity may affect the therapeutic potential of irinotecan in cancer treatment. SN-38 is the active metabolite of irinotecan responsible for its toxicity and antitumor activity [9-11]. Irinotecan is detoxified in part by converting SN-38 to SN-38G through glucuronidation catalyzed by a specific group of uridine diphosphate glucuronosyltransferases (UDPGT) in the liver and intestines, which is coded by *UGT1A* [12, 13]. A portion of irinotecan is degraded *in vivo* to APC, NPC, M1, 2, 3, 4, catalyzed by CYP3A4 and CYP3A5, which are far less toxic than SN-38 [1, 14]. We have been exploring approaches to enhancing the therapeutic selectivity of irinotecan by focusing on selenium-containing compounds. Selenium is an essential trace element and dietary selenium is predominantly in the form of organic compounds, such as 5-methylselenocysteine (MSC), a known antioxidant. It was confirmed that therapeutic doses of selenium effectively protect against irinotecan-induced toxicity in rodent models with the wild-type *Ugt1a* allele [15, 16]. Our results showed that MSC administered prior and concurrently with irinotecan could significantly reduce the toxic effects of irinotecan, allowing the administration of higher dosages, which resulted in improved therapeutic efficacies and cures in tumor xenograft models with the wild-type *Ugt1a* allele [15, 16]. In contrast, using *Ugt1a* mutant rats, MSC did not offer any significant protection from irinotecan-induced toxicity. These data provide further evidence for the role of *Ugt1a* in the detoxification of irinotecan.

RESULTS AND DISCUSSION

In this study, we set out to study the factors associated with the toxicity and detoxification of irinotecan by comparing *Ugt1a* mutant rats and the wild-type controls. We first wanted to confirm the role of the rat ortholog of *UGT1A*, *Ugt1a*, in irinotecan detoxification by comparing the toxic effects of irinotecan on homozygous Gunn rats (j/j), heterozygous Gunn rats (j/+) and wild-type controls. The Gunn rats carry a frameshift mutation, which causes a complete loss of the enzymatic activities of UDPGT coded by the *Ugt1a* locus [17-19]. In the experiments, we used 8-to-12-week-old female j/j and j/+ rats and their wild-type littermates (+/+) as well as Fischer 344/N rats with body weights of 150-180g from Harlan Sprague Dawley Inc. (Indianapolis, IN). Four rats were maintained per cage with water and food *ad libitum*. The experimental procedures were approved by the Institutional Animal Care and Use Committee of Roswell Park Cancer Institute. Irinotecan (CPT-11) was purchased from Pfizer Inc. (Kalamazoo, MI) as a ready-to-use clinical formulation solution in 5 ml vials containing 100 mg drug (20 mg/ml). Irinotecan was given by i.v. injection *via* the animals' tail veins. We established the maximum tolerated dose (MTD) for the different groups of the rats, which was defined as the maximum dose that could be administered to animals, which resulted in no drug-related lethality and body weight loss of less than 20%. After drug administration, the rats were monitored daily for drug-induced toxic effects, including body weight loss, diarrhea, stomatitis and lethality, for a minimum of 2 weeks, and 3-4 times a week thereafter. The differences between the mean values in the different treatment groups were analyzed for significance using one-way analysis of variances (ANOVA) with Tukey-Kramer multiple comparison tests. A *P* value of less than 0.05 was considered statistically significant. The analysis of our experimental data showed that, following a single i.v. injection of irinotecan, the MTD were 200 mg/kg and 25 mg/kg for +/

+ and j/j rats, respectively. Using the daily $\times 3$ schedule, the MTD were 100 mg/kg and 3 mg/kg for +/+ and j/j rats, respectively (Fig. 1; Table 1; *Online Resource* Figs. S2 & S3 and Tables S1 & S3). Our results showed that severe diarrhea is a dosage-limiting condition associated with lethality in the treated rats (Table 1; *Online Resource* Table S3). The plasma concentrations of irinotecan and SN-38 were measured 1 hr after the administration of irinotecan to j/j and +/+ rats using a validated high-performance liquid chromatography method, as previously described [20]. The separation method was carried out on a Waters Nova-Pak C18 column equipped with a μ Bondapak C18 guard column, with the mobile phase consisting of 20% acetonitrile and 80% triethylamine acetate. Detection was by fluorescence with excitation at 370 nm and emission at 510 nm. The limit of quantitation for both was 2.5 ng/ml. Our results showed that the plasma concentrations of irinotecan and SN-38 in j/j rats were higher than those of the wild-type controls (*Online Resource* Table S2), which is consistent with the observations that mutations in the *UGT1A* locus caused the elevated levels of SN-38 in the patients treated with irinotecan [21-23]. The severity of the toxic response in j/+ rats falls between that of j/j and +/+ rats (Table 1; *Online Resource* Fig. S4 and Table S3), reflecting the consequence of copy number variations of the *Ugt1a* gene. These data confirm the critical role of *Ugt1a* in the detoxification of irinotecan.

To determine if the drug specificity for the role of the *Ugt1a* mutation in the detoxifications of irinotecan, we evaluated the toxic effects of different chemotherapeutic agents in rats with different genotypes. The results shown in *Online Resource* Fig. S5 and Table S4 indicated the *Ugt1a* mutation did not adversely affect the MTD or toxic profiles of docetaxel and cisplatin, suggesting that toxicity and detoxification of irinotecan is specifically dependent on *Ugt1a* expression.

To examine the potential role of *Ugt1a* on the observed protection of selenium against irinotecan-associated toxicity in mice and rats with the wild-type *Ugt1a* [15, Cao et al., unpublished data], we evaluated the MTDs and toxic effects of irinotecan alone and in combination with MSC in Gunn rats. MSC was purchased from Sigma (St. Louis, MO) and dissolved in sterile saline (0.9% NaCl) at a concentration of 1 mg/ml. MSC was administered orally (p.o.) once a day at 0.5 mg/rat/day, 7 days before and during and 7 days after irinotecan treatment. Our results indicate that, unlike the animals with the wild-type *Ugt1a* in which MSC offers strong protection against lethal doses of irinotecan and prevents irinotecan-induced diarrhea, bone marrow suppression and lethality [15, Cao et al., unpublished data] MSC did not yield any significant protection in j/j rats (Fig. 1; Table 1). It is interesting to observe that MSC-associated protection was also evident for j/+ rats (*Online Resource* Fig. S6; Table 1), suggesting MSC still played an essential role in alleviating the toxic effects of irinotecan, even when only one copy of *Ugt1a* was functional.

Besides being converted to SN-38 by carboxylesterases, irinotecan can also be metabolized to compounds that have fewer cytotoxic effects than SN-38, which is catalyzed by CYP3A4 and CYP3A5 in rats [1, 14, 24]. Thus, the protective effect of selenium against irinotecan-induced host toxicities could be due to enhanced activities of carboxylesterases/UDPGT encoded by *Ugt1a* and/or *Cyp3a4/Cyp3a5* by selenium. Although it has been reported that selenium could significantly increase expression of *Cyp3a5* [25], it is presently unknown if the expression of *Cyp3a4* is elevated. Promoting expression of *Ugt1a* by selenium has also been reported [26, 27]. If selenium-induced elevation of expression of *Cyp3a4/Cyp3a5* plays a major role in the detoxification of irinotecan, the significant protection of selenium against irinotecan-associated toxicity should have remained even when *Ugt1a* is inactivated. Since our result showed that selenium-induced protection largely disappeared in Gunn rats, it suggests that the *Cyp3a4/Cyp3a5*-mediated metabolic pathway basically did not play a significant role in selenium-mediated protection. Therefore, we have established conclusively for the first time that *Ugt1a* is essential for selenium to exert its protective role

against irinotecan-induced toxicity. Although it is possible that the selenium-induced elevated expression of *Ugt1a* may be a key reason, our results provide a strong impetus to fully explore the mechanistic details related to this phenomenon. Such an effort may lead to a better strategy in using selenium and/or novel modulators to increase the therapeutic efficacies of irinotecan in cancer treatment.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The authors would like to thank the Animal Resources and other core facilities at Roswell Park Cancer Institute for their support. The project is also supported in part by grants from the NIH (R01HL091519 and P30CA016056).

REFERENCES

1. Ma MK, McLeod HL. Lessons learned from the irinotecan metabolic pathway. *Curr Med Chem.* 2003; 10:41–49. [PubMed: 12570720]
2. Rivory LP. Irinotecan (CPT-11): a brief overview. *Clin Exp Pharmacol Physiol.* 1996; 23:1000–1004. [PubMed: 8911750]
3. Lavelle F, Bissery MC, Andre S, Roquet F, Riou JF. Preclinical evaluation of CPT-11 and its active metabolite SN-38. *Semin Oncol.* 1996; 23:11–20. [PubMed: 8633248]
4. Rivory LP, Bowles MR, Robert J, Pond SM. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. *Biochem Pharmacol.* 1996; 52:1103–1111. [PubMed: 8831730]
5. Wiseman LR, Markham A. Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. *Drugs.* 1996; 52:606–623. [PubMed: 8891470]
6. Satoh T, Hosokawa M, Atsumi R, Suzuki W, Hokusui H, Nagai E. Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase. *Biol Pharm Bull.* 1994; 17:662–664. [PubMed: 7920428]
7. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirota N, Elfring GL, Miller LL. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. *N Engl J Med.* 2000; 343:905–914. [PubMed: 11006366]
8. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. *Lancet.* 2000; 355:1041–1047. [PubMed: 10744089]
9. Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. *Cancer Res.* 1994; 54:3723–3725. [PubMed: 8033091]
10. Gupta E, Wang X, Ramirez J, Ratain MJ. Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital. *Cancer Chemother Pharmacol.* 1997; 39:440–444. [PubMed: 9054958]
11. Kojima A, Shinkai T, Saijo N. Cytogenetic effects of CPT-11 and its active metabolite, SN-38 on human lymphocytes. *Jpn J Clin Oncol.* 1993; 23:116–122. [PubMed: 8515576]
12. Atsumi R, Suzuki W, Hokusui H. Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion. *Xenobiotica.* 1991; 21:1159–1169. [PubMed: 1788984]
13. Kaneda N, Yokokura T. Nonlinear pharmacokinetics of CPT-11 in rats. *Cancer Res.* 1990; 50:1721–1725. [PubMed: 2306726]

14. Rivory LP, Riou JF, Haaz MC, Sable S, Vuilhorgne M, Commercon A, Pond SM, Robert J. Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients. *Cancer Res.* 1996; 56:3689–3694. [PubMed: 8706009]
15. Cao S, Durrani FA, Rustum YM. Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts. *Clin Cancer Res.* 2004; 10:2561–2569. [PubMed: 15073137]
16. Fakih M, Cao S, Durrani FA, Rustum YM. Selenium protects against toxicity induced by anticancer drugs and augments antitumor activity: a highly selective, new, and novel approach for the treatment of solid tumors. *Clin Colorectal Cancer.* 2005; 5:132–135. [PubMed: 16098255]
17. Iyanagi T. Molecular basis of multiple UDP-glucuronosyltransferase isoenzyme deficiencies in the hyperbilirubinemic rat (Gunn rat). *J Biol Chem.* 1991; 266:24048–24052. [PubMed: 1748678]
18. Roy-Chowdhury J, Huang TJ, Kesari K, Lederstein M, Arias IM, Roy-Chowdhury N. Molecular basis for the lack of bilirubin-specific and 3-methylcholanthrene-inducible UDP-glucuronosyltransferase activities in Gunn rats. The two isoforms are encoded by distinct mRNA species that share an identical single base deletion. *J Biol Chem.* 1991; 266:18294–18298. [PubMed: 1717446]
19. Chowdhury JR, Kondapalli R, Chowdhury NR. Gunn rat: a model for inherited deficiency of bilirubin glucuronidation. *Adv Vet Sci Comp Med.* 1993; 37:149–173. [PubMed: 8273513]
20. Warner DL, Burke TG. Simple and versatile high-performance liquid chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of camptothecin anticancer drugs. *J Chromatogr B Biomed Sci Appl.* 1997; 691:161–171. [PubMed: 9140770]
21. Ando Y, Saka H, Asai G, Sugiura S, Shimokata K, Kamataki T. UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. *Ann Oncol.* 1998; 9:845–7. [PubMed: 9789606]
22. Paoluzzi L, Singh AS, Price DK, Danesi R, Mathijssen RH, Verweij J, Figg WD, Sparreboom A. Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. *J Clin Pharmacol.* 2004; 44:854–60. [PubMed: 15286088]
23. Toffoli G, Cecchin E. Uridine diphosphoglucuronosyl transferase and methylenetetrahydrofolate reductase polymorphisms as genomic predictors of toxicity and response to irinotecan-, antifolate- and fluoropyrimidine-based chemotherapy. *J Chemother.* 2004; 16(Suppl 4):31–5. [PubMed: 15688606]
24. Santos A, Zanetta S, Cresteil T, Deroussent A, Pein F, Raymond E, Vernillet L, Risse ML, Boige V, Gouyette A, Vassal G. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. *Clin Cancer Res.* 2000; 6:2012–2020. [PubMed: 10815927]
25. Azrak RG, Yu J, Pendyala L, Smith PF, Cao S, Li X, Shannon WD, Durrani FA, McLeod HL, Rustum YM. Irinotecan pharmacokinetic and pharmacogenomic alterations induced by methylselenocysteine in human head and neck xenograft tumors. *Mol Cancer Ther.* 2005; 4:843–854. [PubMed: 15897249]
26. Ip C, Lisk DJ. Modulation of phase I and phase II xenobiotic-metabolizing enzymes by selenium-enriched garlic in rats. *Nutr Cancer.* 1997; 28:184–188. [PubMed: 9290126]
27. Obol'skii OL, Kravchenko LV, Avren'eva LI, Tutel'ian VA. [Effect of dietary selenium on the activity of UDP-glucuronosyltransferases and metabolism of mycotoxin deoxynivalenol in rats]. *Vopr Pitan.* 1998; 67:18–23. [PubMed: 9825468]

Fig. 1.

Toxicity of irinotecan $\pm$ MSC in j/j rats with a single i.v. injection (a) and i.v. injection once a day for three days (i.v. daily $\times$ 3, b) schedules. **a** $\circ$ Control; ∇ Irinotecan 35 mg/kg (50% death); $\blacktriangledown$ Irinotecan 35 mg/kg + MSC 0.5 mg/rat/day (50% death), $\square$ Irinotecan 40 mg/kg (100% death); $\blacksquare$ Irinotecan 40 mg/kg + MSC 0.5 mg/rat/day (100% death). **b** $\circ$ Control; ∇ Irinotecan 4 mg/kg/day (50% death); $\blacktriangledown$ Irinotecan 4 mg/kg/day + MSC 0.5 mg/rat/day (43% death); $\square$ Irinotecan 5 mg/kg/day (83% death); $\blacksquare$ Irinotecan 5 mg/kg/day + MSC 0.5 mg/rat/day (66% death). Additional information on irinotecan and MSC administrations were described in the text. Four rats were used for each experimental group and the experiments were repeated at least once.

Table 1

Effect of MSC on the toxicity of irinotecan in j/j and j/+ rats

Genotype of rats	Drug (dose)	Irinotecan Schedule	Toxicities		
			MWL	Diarrhea	Death
j/j	Irinotecan (40mg/kg)	i.v. × 1	29.2 ± 1.2	100	100
j/j	Irinotecan (40mg/kg) + MSC (0.5 mg/rat/d)	i.v. × 1	31.2 ± 0.8	100	100
j/j	Irinotecan (35mg/kg)	i.v. × 1	26.5 ± 1.4	100	50
j/j	Irinotecan (35mg/kg) + MSC (0.5 mg/rat/d)	i.v. × 1	22.2 ± 2.8	50	50
j/j	Irinotecan (5mg/kg)	i.v. daily × 3	26.6 ± 1.9	100	83
j/j	Irinotecan (5mg/kg) + MSC (0.5 mg/kg/d)	i.v. daily × 3	29.0 ± 3.6	66	66
j/j	Irinotecan (4mg/kg)	i.v. daily × 3	22.8 ± 2.6	50	50
j/j	Irinotecan (4mg/kg) + MSC (0.5 mg/rat/d)	i.v. daily × 3	19.3 ± 2.2	43	43
j/+	Irinotecan (100mg/kg)	i.v. daily × 3	29.5 ± 5.2	100	100
j/+	Irinotecan (100mg/kg) + MSC (0.5 mg/rat/d)	i.v. daily × 3	26.1 ± 6.0	50	50
j/+	Irinotecan (75mg/kg)	i.v. daily × 3	32.0 ± 3.5	100	25
j/+	Irinotecan (75mg/kg) + MSC (0.5 mg/rat/d)	i.v. daily × 3	12.4 ± 3.3	25	0

MSC was administered by p.o. once a day, 7 days before and 7 days after irinotecan, for a total of 14 (i.v. × 1) or 16 (i.v. daily × 3) days. Four rats were used for each experimental group and the experiments were repeated at least once.

MWL maximum body weight loss (%).